Follow us on...
IconTwitterlinkedin





Search News Archives
Search for a Supplier

Company Name:


Location:

Product:

E-Newsletters
E Newsletter sign up
Calendar of events
«  »
SMTWTFS
 12345
6789101112
13141516171819
20212223242526
2728293031 
Social Media
twitter
Facebook
linkedin

Reproducible and Quantifiable Directed In Vivo Angiogenesis Assessment Assays

publication date: Jul 19, 2011
 | 
author/source: Primetek Solutions
Download Print Send a summary of this page to someone via email.
Directed In Vivo Angiogenesis Assessment AssaysAMSBIO has announced a new range of Directed in vivo Angiogenesis Assay (DIVAATM) kits that address the short-comings of the traditional plug assay by controlling the site for angiogenesis, increasing reproducibility, conserving test compounds, and supplying more statistical data for quantitative analysis. This range of kits is designed to test for activation, inhibition and tube formation.

The Directed In Vivo Angiogenesis Assay (DIVAATM) is the first in vivo system for the study of angiogenesis that provides quantitative and reproducible results. The DIVAA kits provide implant grade silicone cylinders closed at one end, called angioreactors. The angioreactors are filled with 20 microlitres of AMSBIO's Basement Membrane Extract (BME) premixed with or without angiogenesis modulating factors. These angioreactors are then implanted subcutaneously in the dorsal flanks of nude mice. With the onset of angiogenesis, cellular vascularization proceeds to invade the angioreactor, and as early as nine days post-implantation, there are enough cells to determine an effective dose response to angiogenic modulating factors. The sleek design of the patented angioreactor optimizes sensitivity and allows for up to four units per mouse, giving a more controlled experiment and decreasing the number of mice required for a study.

Tumour cells can be implanted into the angioreactor, to study their angiogenic effects in an in vivo system. AMSBIO's DIVAA Kit is provided with FITC-Lectin for fluorescent quantitative analysis. Optional protocols are available for analysis with Calcein-AM and Dextran-FITC.

For further information please visit www.amsbio.com/in-vivo-Angiogenesis-Assay-kits-DIVAA.aspx or contact AMSBIO on +44-1235-828200 / +1-949-768-8365 or email info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized as a leading international provider of unique & innovative products & custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal & monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, & tissue DNA, RNA, protein & microarray products. Key research areas include: apoptosis, cell invasion & migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification & stem cell biology.



blog comments powered by Disqus



Can't find what you are looking for?

Company Name:

Location:

Product:



Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have a product enquiry, please contact the supplier directly.


Lab Bulletin is published by newleaf marketing communications ltd
Lab Bulletin 2012 Media information Pack